Christopher W. Lee

1.5k total citations
24 papers, 980 citations indexed

About

Christopher W. Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Christopher W. Lee has authored 24 papers receiving a total of 980 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 4 papers in Immunology. Recurrent topics in Christopher W. Lee's work include Lung Cancer Treatments and Mutations (8 papers), Occupational and environmental lung diseases (7 papers) and Pleural and Pulmonary Diseases (6 papers). Christopher W. Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Occupational and environmental lung diseases (7 papers) and Pleural and Pulmonary Diseases (6 papers). Christopher W. Lee collaborates with scholars based in Canada, United States and Australia. Christopher W. Lee's co-authors include Kim N., Lesley Seymour, Keyue Ding, Frances A. Shepherd, Glenwood Goss, Nevin Murray, Andrew Arnold, Peter Ellis, Kerry J. Savage and Sanjay C. Rao and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Journal of Clinical Epidemiology.

In The Last Decade

Christopher W. Lee

23 papers receiving 958 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher W. Lee Canada	14	520	448	326	129	82	24	980
Kristen J. Pierce United States	14	350 0.7×	209 0.5×	524 1.6×	60 0.5×	105 1.3×	33	1.0k
Jean Pierre Delord France	13	514 1.0×	185 0.4×	233 0.7×	64 0.5×	57 0.7×	20	792
Thomas J. Semrad United States	15	395 0.8×	237 0.5×	257 0.8×	117 0.9×	162 2.0×	51	890
Jean-Luc Breton France	16	956 1.8×	844 1.9×	194 0.6×	198 1.5×	68 0.8×	45	1.2k
Sujana Movva United States	17	590 1.1×	618 1.4×	182 0.6×	98 0.8×	104 1.3×	67	1.1k
Marion Harris Australia	14	504 1.0×	199 0.4×	179 0.5×	92 0.7×	198 2.4×	36	795
Lucien Perey Switzerland	18	444 0.9×	157 0.4×	321 1.0×	109 0.8×	117 1.4×	43	878
Ewa Matczak United States	13	295 0.6×	384 0.9×	282 0.9×	47 0.4×	147 1.8×	24	866
Shinkyo Yoon South Korea	18	565 1.1×	521 1.2×	239 0.7×	50 0.4×	151 1.8×	84	1.1k
Chie-Schin Shih United States	10	553 1.1×	259 0.6×	326 1.0×	25 0.2×	80 1.0×	11	847

Countries citing papers authored by Christopher W. Lee

Since Specialization

Citations

This map shows the geographic impact of Christopher W. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher W. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher W. Lee more than expected).

Fields of papers citing papers by Christopher W. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher W. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher W. Lee. The network helps show where Christopher W. Lee may publish in the future.

Co-authorship network of co-authors of Christopher W. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher W. Lee. A scholar is included among the top collaborators of Christopher W. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher W. Lee. Christopher W. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Pau‐Chung, et al.. (2025). Tegafur-uracil as a Maintenance Therapy for Non-metastatic Nasopharyngeal Carcinoma: Insights from the Literature. Anticancer Research. 45(9). 3617–3628.

Wu, Fengying, et al.. (2023). P2.18-05 Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis. Journal of Thoracic Oncology. 18(11). S383–S383. 1 indexed citations

Chu, Quincy S., Maria Carmela Piccirillo, Laurent Greillier, et al.. (2023). IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.. Journal of Clinical Oncology. 41(17_suppl). LBA8505–LBA8505. 18 indexed citations

Leighl, Natasha B., Scott A. Laurie, Glenwood Goss, et al.. (2020). CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). 9502–9502. 20 indexed citations

Baetz, Tara, Xinni Song, D. Scott Ernst, et al.. (2018). A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.. Journal of Clinical Oncology. 36(15_suppl). TPS9600–TPS9600. 9 indexed citations

Kang, Hyo Jeong, Joon Seok Hong, Chong Jai Kim, et al.. (2017). Umbilical cord-derived mesenchymal stem cell extracts reduce colitis in mice by re-polarizing intestinal macrophages. Scientific Reports. 7(1). 9412–9412. 70 indexed citations

Wheatley‐Price, Paul, Quincy S. Chu, Maria Bonomi, et al.. (2016). A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Journal of Thoracic Oncology. 11(11). 2018–2021. 29 indexed citations

Melosky, Barbara, Helén Anderson, Ronald L. Burkes, et al.. (2015). Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Induced Skin Toxicities in Patients With Metastatic Lung Cancer. Journal of Clinical Oncology. 34(8). 810–815. 64 indexed citations

Melosky, Barbara, Helén Anderson, Ronald L. Burkes, et al.. (2014). Pan-Canadian rash trial with EGFR inhibitors.. Journal of Clinical Oncology. 32(15_suppl). 8013–8013. 3 indexed citations

10.

Karam, Irene, et al.. (2013). Outcomes of Small Cell Lung Cancer Patients Treated With Cisplatin-Etoposide Versus Carboplatin-Etoposide. American Journal of Clinical Oncology. 38(1). 51–54. 30 indexed citations

11.

Laurie, Scott A., Benjamin Solomon, Lesley Seymour, et al.. (2012). A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29.. Journal of Clinical Oncology. 30(15_suppl). 7511–7511. 8 indexed citations

12.

Laurie, Scott A., Ashish Gupta, Quincy S. Chu, et al.. (2011). Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. Journal of Thoracic Oncology. 6(11). 1950–1954. 52 indexed citations

13.

Goss, Glenwood, Andrew Arnold, Frances A. Shepherd, et al.. (2009). Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. Journal of Clinical Oncology. 28(1). 49–55. 186 indexed citations

14.

Lee, Christopher W., et al.. (2008). Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer. 64(3). 308–313. 44 indexed citations

15.

Bezjak, Andrea, Christopher W. Lee, Keyue Ding, et al.. (2008). Quality-of-Life Outcomes for Adjuvant Chemotherapy in Early-Stage Non–Small-Cell Lung Cancer: Results From a Randomized Trial, JBR.10. Journal of Clinical Oncology. 26(31). 5052–5059. 59 indexed citations

16.

Lee, Christopher W., et al.. (2007). P1-140: Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice. Journal of Thoracic Oncology. 2(8). S606–S606. 5 indexed citations

17.

Lee, Christopher W., Karl Bélanger, Sanjay C. Rao, et al.. (2007). A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investigational New Drugs. 26(3). 249–255. 83 indexed citations

18.

Arnold, Andrew, Lesley Seymour, Michael Smylie, et al.. (2007). Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology. 25(27). 4278–4284. 157 indexed citations

19.

Lee, Christopher W. & Kim N.. (2000). The standard of reporting of health-related quality of life in clinical cancer trials. Journal of Clinical Epidemiology. 53(5). 451–458. 74 indexed citations

20.

Lee, Christopher W., et al.. (1993). Epidermal Growth Factor-like Immunoreactivity in the Buccopharyngeal Mucous Glands of Xenopus laevis Tadpoles. General and Comparative Endocrinology. 89(1). 82–90. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact